Collaboration and License Agreements - Schedule of Deferred Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Roche | Completion of Continuing Trials
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	$ 11,820	$ 16,645	$ 17,957
Increase in collaboration revenue receivable			4,000
Recognition as revenue, as the result of performance obligations satisfied	(1,659)	(4,825)	(5,312)
Balance, Ending	10,161	11,820	16,645
Classified as short-term	7,685
Classified as long-term	2,476
Roche | Collaboration and License Agreement | Completion of Continuing Trials
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning			18,000
Balance, Ending	10,200
Classified as short-term	7,700			$ 15,300
Classified as long-term	2,500			2,700
Bristol-Myers Squibb Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	13,287	26,988	27,354
Increase in collaboration revenue receivable		1,250
Recognition as revenue, as the result of performance obligations satisfied	(500)	(14,951)	(366)
Balance, Ending	12,787	13,287	26,988
Classified as short-term	12,787
Bristol-Myers Squibb Company | Research Activities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	840	2,082	2,448
Increase in collaboration revenue receivable		0
Recognition as revenue, as the result of performance obligations satisfied	(500)	(1,242)	(366)
Balance, Ending	340	840	2,082
Classified as short-term	340
Bristol-Myers Squibb Company | Options to License Druggable Target Lesions
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	0	12,459	12,459
Increase in collaboration revenue receivable		1,250
Recognition as revenue, as the result of performance obligations satisfied	0	(13,709)	0
Balance, Ending	0	0	12,459
Classified as short-term	0
Bristol-Myers Squibb Company | Options to License Undruggable Targets
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	12,447	12,447	12,447
Increase in collaboration revenue receivable		0
Recognition as revenue, as the result of performance obligations satisfied	0	0	0
Balance, Ending	12,447	12,447	12,447
Classified as short-term	12,447
Bristol-Myers Squibb Company | Collaboration and License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Classified as short-term	12,800			$ 27,400
Ono Pharmaceutical Company Ltd | Research Activities
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Balance, Beginning	$ 0	10,473	10,473
Recognition as revenue, as the result of performance obligations satisfied		(10,473)	0
Balance, Ending		$ 0	$ 10,473